Biopharma Service Providers Address a Full Plate of Challenges
Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.
Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.
Participants in this discussion included: Don Paul Kovarcik, technical marketing specialist, Ajinomoto Althea; Robert H. DeWit, president of MPI Research; John Allinson, head of biomarker strategy, drug development services at LGC; Michael Lehmann, president, global sales and marketing, Patheon; Brian Hampson, vice-president, global manufacturing sciences and technology, PCT, a Caladrius Company; Fiona Greer, global director, BioPharma Services Development–Life Sciences, SGS; and Peter Soelk, managing director, Vetter Pharma International.
Download the
BioPharm International 2016 Outsourcing Resources eBook.
